BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34680987)

  • 1. Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
    Tang YH; Lin CY; Lai CH
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
    Lightfoot M; Montemorano L; Bixel K
    Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
    Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
    Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic-Based Therapy of Gynecologic Malignancies.
    Markman M
    Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
    Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
    J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
    Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
    Asano H; Oda K; Yoshihara K; Ito YM; Matsumura N; Shimada M; Watari H; Enomoto T
    J Gynecol Oncol; 2022 Jul; 33(4):e55. PubMed ID: 35557035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.
    Rajawat J; Shukla N; Mishra DP
    Front Biosci (Schol Ed); 2017 Jun; 9(3):343-356. PubMed ID: 28410123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
    Marks EI; Brown VS; Dizon DS
    Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
    Burgess BT; Kolesar JM
    Am J Health Syst Pharm; 2018 Nov; 75(21):1697-1707. PubMed ID: 30228165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    Crafton SM; Bixel K; Hays JL
    Gynecol Oncol; 2016 Sep; 142(3):588-96. PubMed ID: 27168003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine for hereditary tumors in gynecologic malignancies.
    Sekine M; Enomoto T
    J Obstet Gynaecol Res; 2021 Aug; 47(8):2597-2606. PubMed ID: 34036697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I
    Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.